Ischemia-Reperfusion Injury Research

Ischemia/Reperfusion (I/R) injury is defined as the cellular damage that results from a period of ischemia that is followed by the reestablishment of the blood supply to the infarcted tissue.Myocardial ischemia, also known as cardiac ischemia, is defined as the deprivation of oxygen and nutrients to the heart. This phenomenon occurs during a myocardial infarction, when an occlusive thrombus within a coronary artery prevents blood supply to the myocardium, but can also occur during cardiac surgery as a result of pharmacological intervention to temporarily stop the heart. Reperfusion restores blood supply to ischemic tissue, but this is paradoxically associated with further tissue damage.

Ischemia-Reperfusion Injury Research Products Targets

Products for Ischemia-Reperfusion Injury Research - Page 19

Cat.No. Product Name Information/Activity
BCC6932 Iberiotoxin 129203-60-7
BCC7710 Kaliotoxin 145199-73-1
BCC6307 NS 6180 NS6180 is a novel potent and selective KCa3.1 channel inhibitor(IC50= 9 nM) prevents T-cell activation and inflammation.
BCC1122 TRAM-34 TRAM-34 is a highly selective blocker of intermediate-conductance calcium-activated K+ channel (IKCa1) (Kd=20 nM).
BCC8038 TRAM 39 Potent K<sub>Ca</sub>3.1 blocker
BCC7016 UCL 1684 199934-16-2
BCC7446 UCL 2077 UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels.
BCC7038 Cromakalim 94470-67-4
BCC6868 Diazoxide Diazoxide (Sch-6783) is an ATP-sensitive potassium channel activator, has the potential for hyperinsulinism treatment.
BCC7039 Levcromakalim Levcromakalim ((-)-Cromakalim) is an ATP-sensitive K+ channel (KATP) activator.